Table 1:
Demographics
| Characteristic | High-Exposure Group (n = 80) | Low-Exposure Group (n = 115) | P Value |
|---|---|---|---|
| Age (yr)a | 51 ± 8 (34–64) | 52 ± 8 (27–82) | NS |
| Sex | |||
| Female | 52 (65%) | 78 (68%) | |
| Male | 28 (35%) | 37 (32%) | |
| Weight (kg)a | 72 ± 16 (48–120) | 71 ± 15 (48–117) | |
| Gadolinium type | |||
| Gadodiamide | 30 (37.5%) | 40 (34.8%) | |
| Gadopentetate dimeglumine | 50 (62.5%) | 75 (65.2%) | |
| Treatment assignment | |||
| MBP8298 | 41 (51%) | 57 (50%) | |
| Placebo | 39 (49%) | 58 (50%) | |
| EDSS at week −4a | 5.57 ± 1.03 (3–6.5) | 5.34 ± 1.13 (3–6.5) | NS |
| EDSS at year 2a | 5.61 ± 1.00 (3.5–6.5) | 5.66 ± 1.19 (2–7.5) | NS |
| Disease duration (yr)a | 13.6 ± 5.5 (4–25) | 11.7 ± 5.1 (2–27) | NS |
| (n = 65) | (n = 84) | ||
| Magnet strength | |||
| 1T | 0 (0%) | 4 (3%) | |
| 1.5T | 58 (73%) | 93 (81%) | |
| 3T | 22 (27%) | 18 (16%) |
Note:—EDSS indicates Expanded Disability Status Scale; NS, not significant.
a
Data are means ± SD (range).